SANARIA INC.

Biotech · Private

Radiation-attenuated and chemoprophylaxis-enhanced Plasmodium falciparum sporozoite (PfSPZ) malaria vaccines

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · sanaria.com

Sector: Biotech
Total capital: $84.6M

Federal grants: $59.6M; 70 awards · 2015–2025; Rank in peer group#38 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $25M; 14 awards · Defense, Health and Human S; Rank in Biotech#34 of 4373
Granted patents: 16; 13 pending · first 2014; Rank in peer group#14 of 514

Capital timeline

Latest events

Jun 2025Federal grantHealth and Human S · Phase II · A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$999K
Aug 2024Federal grantHealth and Human S · Phase I · Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro$278K
Jul 2024Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine$968K
Jun 2024Federal contractHealth and Human S · Pfspz Reagents Biological Kits (ambis #2228227)$64K
Mar 2024Federal grantHealth and Human S · Phase II · A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$999K
Feb 2024Federal grantHealth and Human S · Phase I · Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines$300K
Sep 2023Federal grantHealth and Human S · Phase I · Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro$282K

Show 77 earlier federal awards

Aug 2023Federal contractHealth and Human S · Asexual Malaria Blood Culture Service For Ncats$89K
Jun 2023Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine$968K
May 2023Federal grantHealth and Human S · Phase I · In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine$300K
Apr 2023Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$958K
Mar 2023Federal grantHealth and Human S · Phase II · A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1M
Mar 2023Federal grantHealth and Human S · Phase II · A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$1.0M
Feb 2023Federal grantHealth and Human S · Phase I · Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines$300K
Sep 2022Federal contractHealth and Human S · Sanaria INC.:1161149 [22-005648]$43K
Aug 2022Federal contractHealth and Human S · Sanaria Inc$299K
Jul 2022Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine$999K
Jun 2022Federal grantHealth and Human S · Phase I · In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine$300K
May 2022Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$947K
May 2022Federal grantHealth and Human S · Phase II · Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites$961K
Apr 2022Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$966K
Mar 2022Federal grantHealth and Human S · Phase II · A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1M
Mar 2022Federal grantHealth and Human S · Phase I · Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray$300K
Jan 2022Federal grantHealth and Human S · Phase II · Cryopreservation of Anopheles Embryos$967K
Aug 2021Federal grantHealth and Human S · Phase I · Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture$300K
May 2021Federal grantHealth and Human S · Phase II · Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites$977K
May 2021Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$966K
Apr 2021Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$1M
Apr 2021Federal grantHealth and Human S · Phase II · A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1M
Apr 2021Federal grantHealth and Human S · Phase I · Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray$300K
Apr 2021Federal grantHealth and Human S · Phase I · A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage.$300K
Mar 2021Federal grantHealth and Human S · Phase II · Cryopreservation of Anopheles Embryos$962K
Aug 2020Federal grantHealth and Human S · Phase I · Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture$300K
Jun 2020Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$1M
May 2020Federal grantHealth and Human S · Phase II · Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites$999K
Apr 2020Federal grantHealth and Human S · Phase I · A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage.$300K
Feb 2020Federal grantHealth and Human S · Phase II · Cryopreservation of Anopheles Embryos$1.0M
Feb 2020Federal grantHealth and Human S · Phase I · Genetically Modified Conditional Sexing A. stephensi Line for PfSPZ Manufacture$298K
Sep 2019Federal contractDefense · JW180076 Phase III Clinical Trial$3.4M
Jul 2019Federal grantHealth and Human S · Phase II · Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture$966K
Jun 2019Federal grantHealth and Human S · Phase I · A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products.$300K
Apr 2019Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$976K
Mar 2019Federal grantHealth and Human S · Phase I · Genetically Modified Conditional Sexing A. stephensi Line for PfSPZ Manufacture$296K
Jan 2019Federal grantHealth and Human S · Phase I · Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine$300K
Sep 2018Federal contractHealth and Human S · Sanaria INC.:1161149 [18-003974]$304K
Jul 2018Federal grantHealth and Human S · Phase II · Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture$982K
Jul 2018Federal grantHealth and Human S · Phase I · A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products.$300K
May 2018Federal grantHealth and Human S · Phase II · Universal Attenuated Sporozoite Vaccine and Challenge System$951K
May 2018Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$988K
May 2018Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1M
May 2018Federal grantDefense · Phase II · Delivery System for Cryopreserved Eukaryotic Cell Vaccines$1.0M
Mar 2018Federal grantHealth and Human S · Phase I · Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine$300K
Jan 2018Federal contractDefense · Research And Development Of A Multi Strain Malaria Vaccine$2.8M
Aug 2017Federal grantHealth and Human S · Phase II · Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture$999K
Aug 2017Federal grantHealth and Human S · Phase II · Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture$2.9M
Jun 2017Federal contractDefense · Igf::ot::igf Research And Development$2.4M
Jun 2017Federal grantHealth and Human S · Phase II · Automating mosquito microdissection for a malaria PfSPZ vaccine$998K
Jun 2017Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1M
May 2017Federal grantHealth and Human S · Phase II · Universal Attenuated Sporozoite Vaccine and Challenge System$970K
Apr 2017Federal grantHealth and Human S · Phase I · Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)$300K
Apr 2017Federal contractDefense · Igf::ot::igf Dhp SBIR Phase I Proposal H163-003-0120, Titled "delivery System For Cryopreserved Eukaryotic Cell Vaccines"$150K
Dec 2016Federal grantHealth and Human S · Phase II · Genetically Attenuated PfSPZ Malaria Vaccine$1.0M
Dec 2016Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$1.0M
Sep 2016Federal contractDefense · Purified Vialed Cryopreserved.$67K
Aug 2016Federal grantHealth and Human S · Phase I · PfSPZ Vaccines Quality Systems Manufacturing Regulatory and Clinical Quality and Data Management Support for Product Commercialization$2M
Jul 2016Federal grantHealth and Human S · Phase II · Cryopreservation of Anopheles Embryos$497K
Jun 2016Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$3M
Jun 2016Federal grantHealth and Human S · Phase II · A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1M
Jun 2016Federal grantHealth and Human S · Phase II · Universal Attenuated Sporozoite Vaccine and Challenge System$2.9M
Jun 2016Federal grantHealth and Human S · Phase II · Universal Attenuated Sporozoite Vaccine and Challenge System$989K
Apr 2016Federal grantHealth and Human S · Phase I · Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)$300K
Jan 2016Federal grantHealth and Human S · Phase I · Development of a whole parasite Plasmodium falciparum sexual and mosquito stages Vaccine to Interrupt Malaria Transmission$313K
Dec 2015Federal grantHealth and Human S · Phase II · Genetically Attenuated PfSPZ Malaria Vaccine$1.0M
Dec 2015Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$1.0M
Sep 2015Federal contractDefense · Phase II Development Of Malaria Vaccine Igf::ot::igf$9.5M
Sep 2015Federal contractDefense · Igf::ot::igf Research And Development$5.7M
Jul 2015Federal grantHealth and Human S · Phase II · Plasmodium Falciparum Whole Sporozoite Malaria Vaccine$1.0M
Jun 2015Federal grantHealth and Human S · Phase II · Cryopreservation of Anopheles Embryos$981K
Apr 2015Federal contractDefense · Purified Vialed Cryopreserved,$150K
Feb 2015Federal grantHealth and Human S · Phase I · Development of a whole parasite Plasmodium falciparum sexual and mosquito stages Vaccine to Interrupt Malaria Transmission$301K
Jan 2015Federal grantHealth and Human S · Phase I · Automating mosquito microdissection for a malaria PfSPZ vaccine$300K
Jan 2015Federal grantHealth and Human S · Phase II · Genetically Attenuated PfSPZ Malaria Vaccine$1.0M
Jan 2015Federal grantHealth and Human S · Phase II · In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$1.0M
Jun 2014Federal contractDefense · Product# SAN409, Purification, Vialed,$88K

Federal awards are summed by year (84 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#38 · top 7%
Granted patents#14 · top 3%
Linked publications#25 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 16 granted of 29

May 28, 2026PendingContainer And Cap Assembly For Cryogenic StorageUSPTOApplication 19451457
Jan 20, 2026GrantedContainer And Cap Assembly For Cryogenic StorageUSPTOUS 12,528,084
Dec 2, 2025GrantedMosquito Egg CryopreservationUSPTOUS 12,484,575

Show all 29 patent records

Container And Cap Assembly For Cryogenic StorageMay 28, 2026 · Application 19451457Pending
Container And Cap Assembly For Cryogenic StorageJan 20, 2026 · US 12,528,084Granted
Mosquito Egg CryopreservationDec 2, 2025 · US 12,484,575Granted
Live Attenuated Oral Vaccine Against Shigellosis And Typhoid FeverSep 9, 2025 · US 12,409,213Granted
Infectious Plasmodium Sporozoites Grown In VitroJul 31, 2025 · Application 18946522Pending
Infectious Plasmodium Sporozoites Grown In VitroDec 24, 2024 · US 12,171,822Granted
Neutralizing Antibodies To Plasmodium Falciparum Circumsporozoite Protein And Their UseApr 11, 2024 · Application 18364104Pending
Infectious Plasmodium Sporozoites Grown In VitroJan 30, 2024 · US 11,883,475Granted
Neutralizing Antibodies To Plasmodium Falciparum Circumsporozoite Protein And Their UseSep 19, 2023 · US 11,760,794Granted
Infectious Plasmodium Sporozoites Grown In VitroDec 28, 2021 · US 11,207,395Granted
Neutralizing Antibodies To Plasmodium Falciparum Circumsporozoite Protein And Their UseJun 1, 2021 · US 11,021,535Granted
Cryovial Storage SystemMay 4, 2021 · US 10,995,980Granted
Infectious Plasmodium Sporozoites Grown In VitroOct 15, 2019 · US 10,441,646Granted
Purified Plasmodium and Vaccine CompositionsApr 30, 2019 · US 10,272,146Granted
Infectious Plasmodium Sporozoites Grown In VitroJan 30, 2018 · US 9,878,026Granted
Purified Plasmodium and Vaccine CompositionsApr 11, 2017 · US 9,616,115Granted
Purified Plasmodium and Vaccine CompositionsJan 26, 2016 · US 9,241,982Granted
Purified Plasmodium and Vaccine CompositionMar 31, 2015 · US 8,992,944Granted
Purified Plasmodium and Vaccine CompositionSep 2, 2014 · US 8,821,896Granted
Infectious Plasmodium Sporozoites Grown In VitroApplication 62016981Pending
Infectious Plasmodium Sporozoites Grown In VitroApplication 61987834Pending
Container And Cap Assembly For Cryogenic StorageApplication PCTUS2019066685Pending
Purified Plasmodium And Vaccine CompositionsApplication PCTUS2010020564Pending
Mosquito Egg CryopreservationApplication 62873780Pending
Mosquito Egg CryopreservationApplication PCTUS2020041854Pending
Neutralizing Antibodies To Plasmodium Falciparum Circumsporozoite Protein And Their UseApplication PCTUS2018017826Pending
Cryovial Storage SystemApplication 62487687Pending
Neutralizing Antibodies To Plasmodium Falciparum Circumsporozoite Protein And Their UseApplication 62457720Pending
Infectious Plasmodium Sporozoites Grown In VitroApplication PCTUS2015028890Pending

Recent research by its founders

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial20261 cites
Baseline Treg frequency, Treg-associated immune checkpoint responses, and plasma IL-10 responses during controlled human malaria infection in semi-immune Kenyan adults: a secondary analysis of the CHMI-SIKA Study20260 cites
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial20254 cites

SYNEDGEN, INC.Similar federal contract value in Biotech · $26.6M in contracts
10X Genomics, Inc.Similar federal contract value in Biotech · $26.4M in contracts
GENVEC, INC.Similar federal contract value in Biotech · $25.3M in contracts
Myriad GeneticsSimilar federal contract value in Biotech · $25M in contracts
PARABON NANOLABS, INC.Similar federal contract value in Biotech · $24.7M in contracts
MICROBIOTIX, INC.Similar federal contract value in Biotech · $23.7M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.